You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Transgelin gene is frequently downregulated by promoter DNA hypermethylation in breast cancer
|
|---|---|
| Published in |
Clinical Epigenetics, September 2015
|
| DOI | 10.1186/s13148-015-0138-5 |
| Pubmed ID | |
| Authors |
Nilufer Sayar, Gurbet Karahan, Ozlen Konu, Betul Bozkurt, Onder Bozdogan, Isik G. Yulug |
| Abstract |
CpG hypermethylation in gene promoters is a frequent mechanism of tumor suppressor gene silencing in various types of cancers. It usually occurs at early steps of cancer progression and can be detected easily, giving rise to development of promising biomarkers for both detection and progression of cancer, including breast cancer. 5-aza-2'-deoxycytidine (AZA) is a DNA demethylating and anti-cancer agent resulting in induction of genes suppressed via DNA hypermethylation. Using microarray expression profiling of AZA- or DMSO-treated breast cancer and non-tumorigenic breast (NTB) cells, we identified for the first time TAGLN gene as a target of DNA hypermethylation in breast cancer. TAGLN expression was significantly and frequently downregulated via promoter DNA hypermethylation in breast cancer cells compared to NTB cells, and also in 13/21 (61.9 %) of breast tumors compared to matched normal tissues. Analyses of public microarray methylation data showed that TAGLN was also hypermethylated in 63.02 % of tumors compared to normal tissues; relapse-free survival of patients was worse with higher TAGLN methylation; and methylation levels could discriminate between tumors and healthy tissues with 83.14 % sensitivity and 100 % specificity. Additionally, qRT-PCR and immunohistochemistry experiments showed that TAGLN expression was significantly downregulated in two more independent sets of breast tumors compared to normal tissues and was lower in tumors with poor prognosis. Colony formation was increased in TAGLN silenced NTB cells, while decreased in overexpressing BC cells. TAGLN gene is frequently downregulated by DNA hypermethylation, and TAGLN promoter methylation profiles could serve as a future diagnostic biomarker, with possible clinical impact regarding the prognosis in breast cancer. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 42 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 2% |
| Canada | 1 | 2% |
| Unknown | 40 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 6 | 14% |
| Unspecified | 5 | 12% |
| Student > Master | 5 | 12% |
| Student > Doctoral Student | 5 | 12% |
| Other | 3 | 7% |
| Other | 10 | 24% |
| Unknown | 8 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 19% |
| Biochemistry, Genetics and Molecular Biology | 7 | 17% |
| Agricultural and Biological Sciences | 7 | 17% |
| Unspecified | 5 | 12% |
| Chemistry | 2 | 5% |
| Other | 2 | 5% |
| Unknown | 11 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 October 2015.
All research outputs
#18,427,608
of 22,829,083 outputs
Outputs from Clinical Epigenetics
#999
of 1,256 outputs
Outputs of similar age
#197,363
of 274,283 outputs
Outputs of similar age from Clinical Epigenetics
#36
of 36 outputs
Altmetric has tracked 22,829,083 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,256 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.5. This one is in the 11th percentile – i.e., 11% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 274,283 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 16th percentile – i.e., 16% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 36 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.